


Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-E55F42F8-8E2A-4536-A5EB-FB62EA29CFE4_6_en-US
DOI: https://doi.org/10.31003/USPNF_M33310_06_01
DOI Ref: ng941

© 2025 USPC
Do not distribute

Fludarabine Phosphate



$C_{10}H_{13}FN_5O_7P$ 365.21
9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)-;
9-β-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate) CAS RN®: 75607-67-9; UNII: 1X9VK901SC.

DEFINITION

Fludarabine Phosphate contains NLT 98.0% and NMT 102.0% of fludarabine phosphate ($C_{10}H_{13}FN_5O_7P$), calculated on the anhydrous, solvent-free basis.

[CAUTION]—Fludarabine phosphate is potentially cytotoxic. Great care should be taken to prevent inhaling particles and exposing the skin to it.]

IDENTIFICATION

Change to read:

- **A.** ▲ [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), *Infrared Spectroscopy*: 197A or 197K ▲ (CN 1-May-2020)
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• **PROCEDURE**

Solution A: 10 mM [monobasic potassium phosphate](#)
Mobile phase: [Methanol](#) and *Solution A* (6:94)
Standard solution: 0.02 mg/mL of [USP Fludarabine Phosphate RS](#) in *Mobile phase*
Sample solution: 0.02 mg/mL of Fludarabine Phosphate in *Mobile phase*
Chromatographic system
(See [Chromatography \(621\)](#), *System Suitability*.)
Mode: LC
Detector: UV 260 nm
Column: 4.6-mm × 15-cm; 5-μm packing [L1](#)
Flow rate: 1.0 mL/min
Injection volume: 10 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of fludarabine phosphate ($C_{10}H_{13}FN_5O_7P$) in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Fludarabine Phosphate RS](#) in the *Standard solution* (mg/mL)

C_U = concentration of Fludarabine Phosphate in the *Sample solution* (mg/mL)

Acceptance criteria: 98.0%–102.0% on the anhydrous, solvent-free basis

IMPURITIES

• CHLORIDE

Standard stock solution: 82.4 µg/mL of [sodium chloride](#) in [water](#)

Standard solution: Transfer 2.0 mL of *Standard stock solution* to a test tube, add 13.0 mL of [water](#), and mix.

Sample solution: Transfer 50.0 mg of Fludarabine Phosphate to a test tube, add 15 mL of water to dissolve, and heat gently if necessary.

Analysis: Add 1.0 mL of [nitric acid](#) to the *Standard solution* and *Sample solution*, and place each in separate, colorless test tubes containing 1.0 mL of silver nitrate TS.

Acceptance criteria: NMT 0.2%; the *Sample solution* shows less turbidity than the *Standard solution*.

• LIMIT OF FREE PHOSPHATE

Reagent solution: Mix 4 g of finely powdered [ammonium molybdate](#) and 0.1 g of finely powdered [ammonium vanadate](#) in a 150-mL beaker. Add 70 mL of [water](#), and grind the particles using a glass rod. A clear solution is obtained within a few minutes. Add 20 mL of [nitric acid](#), adjust to room temperature, and dilute with [water](#) to 100 mL.

Standard solution: 7.16 µg/mL of potassium dihydrogen phosphate in [water](#). Transfer 2.0 mL of this solution to a test tube.

Sample solution: Transfer 10 mg of Fludarabine Phosphate in 2.0 mL of [water](#) to a test tube and heat gently.

Blank: 2.0 mL of [water](#) in a test tube

Analysis: To each of the test tubes containing the *Standard solution*, *Sample solution*, and *Blank*, add 2.0 mL of *Reagent solution*.

Acceptance criteria: NMT 0.1%; the color of the *Standard solution* must be more intense than that of the *Blank*. Viewed downward in diffuse daylight against a white background, the yellow coloration of the *Sample solution* must not be more intense than that of the *Standard solution*.

• LIMIT OF SODIUM

Standard stock solution: 2.54 mg/mL of [sodium chloride](#) in [water](#). [Sodium chloride](#) is previously dried at 105° for 2 h.

Standard solution: 1 µg/mL of sodium in water, from *Standard stock solution*

Sample solution: 0.5 mg/mL of Fludarabine Phosphate in water

Instrumental conditions

Mode: Flame photometry

Analytical wavelength: Sodium emission line at 589.0 nm

Blank: Water

Analysis

Samples: *Standard solution* and *Sample solution*

Acceptance criteria: NMT 0.2%; the emission response of the *Sample solution* is NMT that of the *Standard solution*.

• ORGANIC IMPURITIES, PROCEDURE 1: EARLY-ELUTING IMPURITIES

Mobile phase, Standard solution, and Chromatographic system: Proceed as directed in the Assay.

System suitability solution: 10 mg of Fludarabine Phosphate in 10 mL of [0.1 N hydrochloric acid](#). Heat the solution at 80° in a water bath for 15 min.

Sensitivity solution: 0.5 µg/mL of [USP Fludarabine Phosphate RS](#) in *Mobile phase*, from the *Standard solution*

Sample solution: 1 mg/mL of Fludarabine Phosphate in *Mobile phase*

System suitability

Samples: *Standard solution*, *System suitability solution*, and *Sensitivity solution*

Suitability requirements

Resolution: NLT 2.0 between the iso-ara-guanine monophosphate and isoguanine peaks, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of each early-eluting impurity in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_U/r_S) \times (1/F_1) \times 100$$

r_U = peak response of each individual impurity from the *Sample solution*

r_S = peak response of fludarabine phosphate from the *Sample solution*

F_1 = relative response factor for each individual impurity (see [Table 1](#))

Acceptance criteria: See [Table 1](#).

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Iso-ara-guanine-monophosphate ^a	0.26	0.25	0.8
Isoguanine ^b	0.34	0.40	0.2
3',5'-Diphosphate analog ^c	0.42	0.53	0.4
Any individual, unspecified impurity	<1.0	1.0	0.1
Fludarabine phosphate	1.0	—	—

^a 6-Amino-9-β-D-arabinofuranosyl-2-oxo-1H-purine 5'-(dihydrogen phosphate).

^b 6-Amino-1H-purin-2(9H)-one.

^c 9-β-D-Arabinofuranosyl-2-fluoroadenine 3',5'-bis(dihydrogen phosphate).

• **ORGANIC IMPURITIES, PROCEDURE 2: LATE-ELUTING IMPURITIES**

Solvent A: 10 mM [monobasic potassium phosphate](#)

Mobile phase: [Methanol](#) and Solvent A (1:4)

Standard solution and Chromatographic system: Proceed as directed in the Assay.

Sensitivity solution and Sample solution: Prepare as directed in *Organic Impurities, Procedure 1: Early-Eluting Impurities*.

System suitability

Samples: *Standard solution and Sensitivity solution*

Suitability requirements

Tailing factor: NMT 2.0, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of each late-eluting impurity in the portion of Fludarabine Phosphate taken:

$$\text{Result} = (r_U/r_S) \times (1/F_2) \times 100$$

r_U = peak response of each individual impurity from the *Sample solution*

r_S = peak response of fludarabine phosphate from the *Sample solution*

F_2 = relative response factor for each individual impurity (see [Table 2](#))

Acceptance criteria: See [Table 2](#).

Table 2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Fludarabine phosphate	1.0	—	—
2-Fluoroadenine ^a	1.5	2.0	0.1
2-Fluoro-ara-adenine ^b	1.9	1.7	0.2
2-Ethoxyphosphate analog ^c	2.5	0.56	0.2

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)
Any individual, unspecified impurity	>1.0	1.0	0.1
Total unspecified impurities ^d	—	—	0.5
Total impurities ^e	—	—	1.5

^a 2-Fluoro-9H-purin-6-amine.

^b 9-β-D-Arabinofuranosyl-2-fluoroadenine.

^c 2-Ethoxy-9-β-D-arabinofuranosyladenine 5'-(dihydrogen phosphate).

^d The sum of all unspecified impurities found in *Organic Impurities, Procedure 1: Early-Eluting Impurities* and *Organic Impurities, Procedure 2: Late-Eluting Impurities*.

^e The sum of all impurities found in *Organic Impurities, Procedure 1: Early-Eluting Impurities* and *Organic Impurities, Procedure 2: Late-Eluting Impurities*.

• **LIMIT OF ALCOHOL**

Standard solution: 0.50 mg/mL of [alcohol](#) in [dimethylformamide](#)

Sample solution: 50 mg/mL of Fludarabine Phosphate in [dimethylformamide](#)

Blank: [Dimethylformamide](#)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: GC equipped with a headspace injector

Detector: Flame ionization

Column: 0.25-mm × 30-m; 1.4-μm coating of phase [G43](#)

Temperatures

Injection port: 160°

Detector: 250°

Column: See [Table 3](#).

Table 3

Initial Temperature (°)	Temperature Ramp (°/min)	Final Temperature (°)	Hold Time at Final Temperature (min)
40	0	40	10
40	5	70	—
70	30	220	—

Carrier gas: Helium

Flow rate: 27 cm/s

Sample

Volume: 2 mL/vial. [NOTE—Seal the vials using a flanged cap so that the cap can no longer be turned.]

Conditioning temperature: 80°

Conditioning time: 60 min

Injection volume: 1.0 mL

System suitability

Samples: *Standard solution* and *Blank*

[NOTE—The retention time for alcohol is about 3 min.]

Suitability requirements

Relative standard deviation: NMT 4.0% for three injections, *Standard solution*

Peak interference: No peak at the retention time for alcohol, *Blank*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of alcohol in the portion of Fludarabine Phosphate taken:

r_U = peak area of alcohol from the *Sample solution*
 r_S = peak area of alcohol from the *Standard solution*
 C_S = concentration of alcohol in the *Standard solution* (mg/mL)
 C_U = concentration of Fludarabine Phosphate in the *Sample solution* (mg/mL)

[NOTE—Use the percentage obtained to calculate the Assay result on the solvent-free basis.]

Acceptance criteria: NMT 1.0%

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total aerobic microbial count is NMT 10³ cfu/g.
- [OPTICAL ROTATION \(781S\)](#), [Procedures, Specific Rotation](#)
Sample solution: 5 mg/mL in water
Acceptance criteria: +10° to +14°
- [WATER DETERMINATION \(921\)](#), [Method I](#): NMT 3.0%

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed, light-resistant containers, and store in a refrigerator.
- [USP REFERENCE STANDARDS \(11\)](#)
[USP Fludarabine Phosphate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FLUDARABINE PHOSPHATE	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 43(5)

Current DocID: GUID-E55F42F8-8E2A-4536-A5EB-FB62EA29CFE4_6_en-US
DOI: https://doi.org/10.31003/USPNF_M33310_06_01
DOI ref: [ng941](#)